Please use this identifier to cite or link to this item:
|Title:||Impact of an alternating first-line antibiotics strategy in febrile neutropenia||Authors:||Tan B.H.
Torres De Guzman M.R.
Sioco Donato L.K.
piperacillin plus tazobactam
all cause mortality
Antibiotic Heterogeneity Index
major clinical study
methicillin resistant Staphylococcus aureus
vancomycin resistant Enterococcus
Aged, 80 and over
Drug Resistance, Bacterial
Practice Patterns, Physicians'
|Issue Date:||2018||Citation:||Tan B.H., Torres De Guzman M.R., Sioco Donato L.K., Kalimuddin S., Lee W.H.L., Tan A.L., Wong G.C. (2018). Impact of an alternating first-line antibiotics strategy in febrile neutropenia. PLoS ONE 13 (11) : e0208039. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0208039||Abstract:||Background Rising antibiotic resistance poses a challenge to the management of febrile neutropenia in patients with haematological malignancies receiving chemotherapy. Aim We studied an alternating first-line antibiotic strategy to determine its impact on all-cause mortality and bacteremia rates in patients with febrile neutropenia. Methods An alternating first-line antibiotic strategy was established in mid-2013. Data for 2012 (before strategy implementation) and 2014 (post-strategy implementation) were compared. Antibiotic Heterogeneity Index (AHI) for each of the two time-periods was also calculated. Findings There were 2012 admissions (26082 patient-days) in 2012 and 1843 admissions (24331 patient-days) in 2014. There was no significant difference in the baseline characteristics of patients in the two groups. The defined daily doses (DDD) of cefepime (CEF) fell while the DDD of piperacillin-tazobactam (PTZ) rose in 2014 compared with 2012. Vancomycin DDD fell in 2014. The AHI was 0.466 in 2012 and 0.582 in 2014. The difference in all-cause mortality was not statistically significant. There was no difference in rates of bacteremia with CEF-resistant, PTZ-resistant and carbapenem-resistant gram-negative organisms in the two groups. Rates of new cases of Methicillin-resistant Staphylococcus aureus (MRSA) were 2.38/1000 and 2.59/1000 patient-days in 2012 and 2014 respectively. Rates of new cases of Vancomycin-resistant Enterococcus (VRE) were 1.84/1000 and 1.81/1000 patient-days in 2012 and 2014 respectively. There was no Carbapenem-resistant Enterobacteriaceae (CRE) bacteremia in 2012 and 1 in 2014. Conclusion An alternating first-line antibiotic strategy resulted in an increase in antibiotic heterogeneity, without increasing mortality. There was also no significant increase in bacteremia rates. © 2018 Tan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.||Source Title:||PLoS ONE||URI:||https://scholarbank.nus.edu.sg/handle/10635/161207||ISSN:||19326203||DOI:||10.1371/journal.pone.0208039|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|10_1371_journal_pone_0208039.pdf||736.08 kB||Adobe PDF|
checked on Mar 26, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.